My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 626

    1.

    Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial.

    de Valk HW, Banga JD, Wester JW, Brouwer CB, van Hessen MW, Meuwissen OJ, Hart HC, Sixma JJ, Nieuwenhuis HK.

    Ann Intern Med. 1995 Jul 1;123(1):1-9.PMID: 7539233 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.

    Merli G, Spiro TE, Olsson CG, Abildgaard U, Davidson BL, Eldor A, Elias D, Grigg A, Musset D, Rodgers GM, Trowbridge AA, Yusen RD, Zawilska K; Enoxaparin Clinical Trial Group.

    Ann Intern Med. 2001 Feb 6;134(3):191-202.PMID: 11177331 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Risk factors for bleeding during treatment of acute venous thromboembolism.

    Wester JP, de Valk HW, Nieuwenhuis HK, Brouwer CB, van der Graaf Y, Meuwissen OJ, Hart HC, Sixma JJ, Banga JD.

    Thromb Haemost. 1996 Nov;76(5):682-8.PMID: 8950773 [PubMed - indexed for MEDLINE]Related articles

    4.

    Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism.

    Kearon C, Ginsberg JS, Julian JA, Douketis J, Solymoss S, Ockelford P, Jackson S, Turpie AG, MacKinnon B, Hirsh J, Gent M; Fixed-Dose Heparin (FIDO) Investigators.

    JAMA. 2006 Aug 23;296(8):935-42.PMID: 16926353 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators.

    [No authors listed]

    JAMA. 1998 Apr 22-29;279(16):1265-72.PMID: 9565006 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Danaparoid for heparin-induced thrombocytopenia: an analysis of treatment failures.

    Kodityal S, Manhas AH, Udden M, Rice L.

    Eur J Haematol. 2003 Aug;71(2):109-13.PMID: 12890149 [PubMed - indexed for MEDLINE]Related articles

    7.

    Low-molecular-weight heparinoid orgaran is more effective than aspirin in the prevention of venous thromboembolism after surgery for hip fracture.

    Gent M, Hirsh J, Ginsberg JS, Powers PJ, Levine MN, Geerts WH, Jay RM, Leclerc J, Neemeh JA, Turpie AG.

    Circulation. 1996 Jan 1;93(1):80-4.PMID: 8616946 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.

    Breddin HK, Hach-Wunderle V, Nakov R, Kakkar VV; CORTES Investigators. Clivarin: Assessment of Regression of Thrombosis, Efficacy, and Safety.

    N Engl J Med. 2001 Mar 1;344(9):626-31.PMID: 11228276 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    A low-molecular-weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. A randomized, double-blind study.

    Turpie AG, Gent M, Côte R, Levine MN, Ginsberg JS, Powers PJ, Leclerc J, Geerts W, Jay R, Neemeh J, et al.

    Ann Intern Med. 1992 Sep 1;117(5):353-7.PMID: 1503326 [PubMed - indexed for MEDLINE]Related articles

    10.

    Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin-Study Group.

    Kirchmaier CM, Wolf H, Schäfer H, Ehlers B, Breddin HK.

    Int Angiol. 1998 Sep;17(3):135-45.PMID: 9821025 [PubMed - indexed for MEDLINE]Related articles

    11.

    Use of a low-molecular-weight heparinoid (danaparoid sodium) for continuous renal replacement therapy in intensive care patients.

    Lindhoff-Last E, Betz C, Bauersachs R.

    Clin Appl Thromb Hemost. 2001 Oct;7(4):300-4.PMID: 11697713 [PubMed - indexed for MEDLINE]Related articles

    12.

    Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: a clinical outcome study.

    Chong BH, Gallus AS, Cade JF, Magnani H, Manoharan A, Oldmeadow M, Arthur C, Rickard K, Gallo J, Lloyd J, Seshadri P, Chesterman CN; Australian HIT Study Group.

    Thromb Haemost. 2001 Nov;86(5):1170-5.PMID: 11816702 [PubMed - indexed for MEDLINE]Related articles

    13.

    Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials.

    Quinlan DJ, McQuillan A, Eikelboom JW.

    Ann Intern Med. 2004 Feb 3;140(3):175-83.PMID: 14757615 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.

    Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, van den Berg-Segers AE, Cariou R, Leeuwenkamp O, Lensing AW; Matisse Investigators.

    N Engl J Med. 2003 Oct 30;349(18):1695-702. Erratum in: N Engl J Med. 2004 Jan 22;350(4):423. PMID: 14585937 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Danaparoid: a review of its use in thromboembolic and coagulation disorders.

    Ibbotson T, Perry CM.

    Drugs. 2002;62(15):2283-314. Review.PMID: 12381232 [PubMed - indexed for MEDLINE]Related articles

    16.

    A multicentre, double-blind, randomized study to compare the safety and efficacy of once-daily ORG 10172 and twice-daily low-dose heparin in preventing deep-vein thrombosis in patients with acute ischaemic stroke.

    Dumas R, Woitinas F, Kutnowski M, Nikolic I, Berberich R, Abedinpour F, Zoeckler S, Gregoire F, Jerkovic M, Egberts JF, et al.

    Age Ageing. 1994 Nov;23(6):512-6.PMID: 9231947 [PubMed - indexed for MEDLINE]Related articles

    17.

    Frequency of major hemorrhage in patients treated with unfractionated intravenous heparin for deep venous thrombosis or pulmonary embolism: a study in routine clinical practice.

    Zidane M, Schram MT, Planken EW, Molendijk WH, Rosendaal FR, van der Meer FJ, Huisman MV.

    Arch Intern Med. 2000 Aug 14-28;160(15):2369-73.PMID: 10927736 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia.

    Tardy-Poncet B, Tardy B, Reynaud J, Mahul P, Mismetti P, Mazet E, Guyotat D.

    Chest. 1999 Jun;115(6):1616-20.PMID: 10378558 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group.

    Colwell CW Jr, Spiro TE, Trowbridge AA, Morris BA, Kwaan HC, Blaha JD, Comerota AJ, Skoutakis VA.

    J Bone Joint Surg Am. 1994 Jan;76(1):3-14. Erratum in: J Bone Joint Surg Am 1994 Mar;76(3):4741. PMID: 8288662 [PubMed - indexed for MEDLINE]Related articles

    20.

    Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group.

    Hull RD, Raskob GE, Brant RF, Pineo GF, Elliott G, Stein PD, Gottschalk A, Valentine KA, Mah AF.

    Arch Intern Med. 2000 Jan 24;160(2):229-36.PMID: 10647762 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity